|
業務類別
|
Biotechnology |
|
業務概覽
|
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer(Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. |
| 公司地址
| 10275 Science Center Drive, Suite 200, San Diego, CA, USA, 92121 |
| 電話號碼
| +1 858 263-4333 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.zentalis.com |
| 員工數量
| 166 |
| Dr. Ingmar Bruns |
Chief Medical Officer |
-- |
30/04/2025 |
| Ms. Julie M. Eastland |
Chief Executive Officer, President and Director |
美元 94.23K |
30/04/2025 |
| Dr. Mark Lackner, PhD |
Chief Scientific Officer |
美元 484.40K |
29/04/2024 |
| Mr. Vincent A Vultaggio |
Senior Vice President, Finance, Principal Accounting Officer and Interim Principal Financial Officer |
-- |
26/03/2025 |
| Mr. James B. Bucher |
Chief Legal Officer and Corporate Secretary |
-- |
26/08/2025 |
|
|
| Mr. Scott D. Myers, M.B.A. |
Chairman of the Board |
30/04/2025 |
| Ms. Julie M. Eastland |
Chief Executive Officer, President and Director |
30/04/2025 |
| Dr. Luke Nathaniel Walker, M.D. |
Independent Director |
30/04/2025 |
| Mr. David M. Johnson |
Independent Director |
30/04/2025 |
| Dr. Enoch Kariuki, Pharm.D. |
Independent Director |
30/04/2025 |
| Dr. Jan Skvarka, M.B.A.,PhD |
Independent Director |
30/04/2025 |
|
|
|
|
